Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.

IF 2.9 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-24 DOI:10.1080/14737140.2023.2236793

Rebecca L Porter, Ursula A Matulonis

{"title":"Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.","authors":"Rebecca L Porter, Ursula A Matulonis","doi":"10.1080/14737140.2023.2236793","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Mirvetuximab soravtansine (mirvetuximab) is an antibody drug conjugate (ADC) comprised of a humanized folate receptor alpha (FRα)-binding monoclonal antibody attached via a cleavable linker to the cytotoxic maytansinoid molecule, DM4. FRα is expressed in several epithelial cancers, including high grade serous ovarian cancer (HGSOC). Mirvetuximab received accelerated approval by the United States Food and Drug Administration (FDA) in November 2022 based on the results of the SORAYA trial, which tested mirvetuximab for the treatment of patients with recurrent platinum resistant HGSOC with high FRα expression and showed an overall response rate (ORR) of 32.4% and a median duration of response of 6.9 months. Mirvetuximab toxicities included low grade ocular and gastrointestinal toxicities. The National Comprehensive Cancer Network (NCCN) ovarian cancer 2023 guidelines adopted mirvetuximab as 2A, and mirvetuximab combined with bevacizumab as 2B, recommendations. Areas covered This manuscript will review the preclinical and clinical development of mirvetuximab, the toxicities associated with mirvetuximab and mitigation strategies, and future applications of mirvetuximab. Expert opinion Mirvetuximab represents the first biomarker-directed therapy with an indication specifically for the treatment of PROC. The efficacy and favorable safety profile support further development of mirvetuximab and mirvetuximab combinations in platinum sensitive and newly diagnosed ovarian cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 8","pages":"783-796"},"PeriodicalIF":2.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2236793","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

ABSTRACT Introduction Mirvetuximab soravtansine (mirvetuximab) is an antibody drug conjugate (ADC) comprised of a humanized folate receptor alpha (FRα)-binding monoclonal antibody attached via a cleavable linker to the cytotoxic maytansinoid molecule, DM4. FRα is expressed in several epithelial cancers, including high grade serous ovarian cancer (HGSOC). Mirvetuximab received accelerated approval by the United States Food and Drug Administration (FDA) in November 2022 based on the results of the SORAYA trial, which tested mirvetuximab for the treatment of patients with recurrent platinum resistant HGSOC with high FRα expression and showed an overall response rate (ORR) of 32.4% and a median duration of response of 6.9 months. Mirvetuximab toxicities included low grade ocular and gastrointestinal toxicities. The National Comprehensive Cancer Network (NCCN) ovarian cancer 2023 guidelines adopted mirvetuximab as 2A, and mirvetuximab combined with bevacizumab as 2B, recommendations. Areas covered This manuscript will review the preclinical and clinical development of mirvetuximab, the toxicities associated with mirvetuximab and mitigation strategies, and future applications of mirvetuximab. Expert opinion Mirvetuximab represents the first biomarker-directed therapy with an indication specifically for the treatment of PROC. The efficacy and favorable safety profile support further development of mirvetuximab and mirvetuximab combinations in platinum sensitive and newly diagnosed ovarian cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Mirvetuximab soravtansine治疗卵巢上皮性癌症铂耐药性。

简介：Mirvetuximab soravtansine（Mirvetu昔mab）是一种抗体-药物偶联物（ADC），由人源化叶酸受体α（FRα）结合单克隆抗体组成，通过可裂解的接头连接到细胞毒性美他新素分子DM4。FRα在几种上皮癌中表达，包括高级别浆液性卵巢癌症（HGSOC）。2022年11月，根据SORAYA试验的结果，Mirvetuximab获得了美国食品药品监督管理局（FDA）的加速批准，该试验测试了Mirvetu昔mab用于治疗高FRα表达的复发性铂耐药性HGSOC患者，显示出32.4%的总有效率（ORR）和6.9的中位反应持续时间月。Mirvetuximab毒性包括低度眼部和胃肠道毒性。国家癌症综合网络（NCCN）卵巢癌症2023年指南采用了美韦妥昔单抗作为2A，美韦妥妥昔单抗联合贝伐单抗作为2B，建议。涵盖领域：本文将综述米韦妥昔单抗的临床前和临床发展、与米韦妥妥昔单抗相关的毒性和缓解策略，以及米韦妥单抗的未来应用。专家意见：Mirvetuximab是第一种生物标志物导向的治疗方法，具有专门治疗PROC的适应症。疗效和良好的安全性支持在铂敏感和新诊断的卵巢癌症中进一步开发米韦妥昔单抗和米韦妥妥昔单抗组合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.